Syndax Pharmaceuticals (SNDX) Misses Q4 EPS by 2c, Miss on Revenues

Note: EPS may not be comparable

Syndax Pharmaceuticals (NASDAQ: SNDX) reported Q4 EPS of ($0.80), $0.02 worse than the analyst estimate of ($0.78). Revenue for the quarter came in at $1.19 million versus the consensus estimate of $1.65 million.

For earnings history and earnings-related data on Syndax Pharmaceuticals (SNDX) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Morgan Stanley sees little room left in steel rally, cuts Cleveland-Cliffs rating
• Ridgepost Capital acquires Stellus Capital Management for $4B AUM